Auxilium Pharmaceuticals — Q2 2013 Earnings Presentation
28 slides from Auxilium Pharmaceuticals's earnings presentation, Aug 1, 2013
Slide 1: Second Quarter 2013 Earnings Call
Second Quarter 2013 Earnings Call August 1, 2013
Slide 2: Forward-looking statements
We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding: whether our strategic commercial and tactical initiatives will hel
Slide 3: Introduction
Introduction 2
Slide 4: Today's Web Cast Agenda
Today’s Web Cast Agenda 2Q & YTD 2013 Corporate Performance Adrian Adams Overview of 2Q13 and Recent Events Actient Integration Update Portfolio Performance 2Q & YTD 2013 Financial Performance Jim Fickenscher Non-GAAP Financials Financial Considerations and Guidance 2013 Expectations and Near-Term P
Slide 5: Overview of 2Q13 and Recent Events
Overview of 2Q13 and Recent Events FINANCIAL and COMMERCIAL(1) Total net revenues of $100.5MM (+29% vs. 2Q12 ) Global Testim® revenue of $54.4MM (-15% vs. 2Q12) Global XIAFLEX® revenue of $18.9MM; U.S. XIAFLEX revenue of $15.0MM (+26% vs. 2Q12) Testopel® revenue of $14.4MM and Edex® revenue of $5.0M
Slide 6: Actient Acquisition – Strategic Rationale
Actient Acquisition – Strategic Rationale Creates a Leading Urology Franchise Diversifies and Balances Product Portfolio Enhances Existing Commercial Efforts Through Combined Sales Force Strong Growth Profile with Expanding Margins Financially Compelling +
Slide 7: Actient integration and run-rate synergy goal
Excellent progress toward end of year 2014 run-rate synergy goal of $20 million: All Actient employees notified of status. Approximately 70 positions have been eliminated. Personnel exits began in Q2 and transition personnel will exit in Aug. and Dec. 2013 Other synergies include consolidation and/o
Slide 8: Sales Force Structure and Responsibilities
Primera Innovia Agilis Number of Territories 150 60 47 Customer Focus Uro, Endo, PCP Uro Ortho Channel Focus Retail Buy & Bill Buy & Bill Current Products Future Products* Sales Force Structure and Responsibilities 7 * If approved by the FDA for Peyronie’s disease indication, Innovia sales force wil
Slide 9: Non-GAAP Operating Expense Leverage Continues to Improve
Non- GAAP Operating Expense Leverage Continues to Improve 92.2% 85.0% 71.4% Note: See appendix for GAAP to non-GAAP reconciliations and explanations 67.7%
Slide 10: Testim – 2Q13 Commercial Performance
Testim – 2Q13 Commercial Performance TRT Gel Market Dynamics 2Q13 Prescriptions: +4.4% vs. 2Q12 1H13 Prescriptions: +7.4% vs. 1H12 Now estimating full-year market growth in mid- to high single digits Testim Overview 2Q13 U.S. net revenue of $53.2MM; -15% vs. 2Q12 Testim quarterly market share loss s
Slide 11: XIAFLEX – 2Q13 Commercial Performance
XIAFLEX-2Q13 Commercial Performance 632 Vials sold to 230 Sites in Q2 ‘10 3,070 Vials sold to 774 Sites in Q2 ‘11 4,182 Vials sold to 1,049 Sites in Q2 ‘12 1Minor historical adjustments may affect historical demand figures over time 4,802 Vials sold to 1,194 Sites in Q2 ‘13 XIAFLEX Performance 2Q13
Slide 12: Testopel – 2Q13 Commercial Performance
Testopel Performance April 261 – June 2013 Testopel U.S. net revenues were $14.4 MM We believe Q2 pellet sales reflect fulfillment of back orders due to stock-out situation in Q4 2012 Testopel Overview Approximately 2,000 unique physicians or sites purchased Testopel in the past 12 months URO Buy an
Slide 13: Edex – 2Q13 Commercial Performance
Edex Performance April 261 – June Edex U.S. net revenues were $ 5.0 MM Retail market share grew 2% in 2Q13 vs. 1Q13, and 8% vs. 2Q122 Mar 2013 12-Month Institutional share: 48%2 ~7,300 physicians prescribed Edex in the retail setting the last 12 months Edex Overview Now being promoted alongside Test
Slide 14: 2Q13 – Strong Revenue Growth
2Q13 – Strong Revenue Growth $78.2 $100.5 +29%
Slide 15: 2Q13 Non-GAAP Financial Results
1 See Appendix for reconciliation of the pro forma non-GAAP financial measures to the closest GAAP financial measures 2 Weighted average common shares were 49.5mm in 2Q2013 and 49.4mm in 2Q2012 Total revenues $78.2 $100.5 29% Cost of goods sold 17.8 22.7 28% Gross Profit $60.4 $77.8 29% % of revenue
Slide 16: Actient Revenues – Jan to April 26, 2013
Actient Revenues – Jan 1 to April 26, 2013 We believe that approximately $7 million of Testopel revenues recorded January 1 to April 25, 2013 were fulfillment of back orders following the 2012 out of stock situation $49.1
Slide 17: Updated 2013 Guidance
Total Revenues $360 – 415 $363 – 405 Global Testim Revenues $210 – 240 $210 – 225 XIAFLEX: U.S. Revenues $55 – 65 $55 – 65 Ex-U.S. / Def. Rev $10 – 15 $13 – 15 Total XIAFLEX Revenues $65 - 80 $68 - 80 Testopel Revenues2,3 N/A $45 – 55 Other Revenues2 N/A $40 - 45 Total Actient Revenues4 $85 - 95 $85
Slide 18: The Broadened Auxilium Portfolio
Therapeutic Area Nonclinical Phase I Phase II Phase III Approved Urology Male Hypogonadism Testim 1% Male Hypogonadism TESTOPEL Erectile Dysfunction Edex® Erectile Dysfunction Osbon ErecAid® Male Hypogonadism Striant ® Peyronie’s disease CCH Male Hypogonadism T-gel Orthopedics Dupuytren’s contractur
Slide 19: Auxilium: Our Near Term Priorities
Auxilium: Our Near Term Priorities Efficiently integrate Actient, deliver on synergies/cost efficiencies Maximize value of current portfolio Stabilize Testim market share & increase unit sales Drive to standard of care in Dupuytren’s for XIAFLEX Grow TESTOPEL and Edex use with Urologists Prepare for
Slide 20: Questions & Answers
Questions & Answers
Slide 21: Second Quarter 2013 Earnings Call
Second Quarter 2013 Earnings Call August 1, 2013
Slide 22: Appendix
Appendix
Slide 23: Non-GAAP financial measures notice
This presentation contains pro-forma financial measures that are not consistent with the financial measures that would be reported in financial statements prepared in accordance with generally accepted accounting principles, or GAAP. These non-GAAP financial measures should not be relied upon as an
Slide 24: Reconciliation of GAAP to Non-GAAP Net Income – 3 Months
Auxilium Reconciliation of GAAP to Non-GAAP Net Income (Loss) 3 Months Ended June 30, 2013 3 Months Ended June 30, 2012 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Net revenues* 100.5 $ - $ 100.5 $ 78.2 $ - $ 78.2 $ Operating expenses: Cost of goods sold 27.2 (4.5) (a) 22.7 17.8 0.0 (a) 17.8
Slide 25: Reconciliation of GAAP to Non-GAAP Net Income – 3 Months Adjustments
Auxilium Reconciliation of GAAP to Non-GAAP Net Income (Loss) 3 Months 3 Months Ended June 30, 2013 Ended June 30, 2012 Adjustments to: (a) Costs of goods sold: Employee stock-based compensation (1) (0.0) $ 0.0 $ Acquired inventory step -up value (2) (4.5) - Total (4.5) $ 0.0 $ (b) Research and deve
Slide 26: Reconciliation of GAAP to Non-GAAP Net Income – 6 Months
Auxilium Reconciliation of GAAP to Non-GAAP Net Income (Loss) 6 Months Ended June 30, 2013 6 Months Ended June 30, 2012 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Net revenues* 166.7 $ - $ 166.7 $ 151.8 $ - $ 151.8 $ Operating expenses: Cost of goods sold 42.3 (4.6) (a) 37.7 34.4 (0.0) (a)
Slide 27: Reconciliation of GAAP to Non-GAAP Net Income – 6 Months Adjustments
Auxilium Reconciliation of GAAP to Non-GAAP Net Income (Loss) 6 Months 6 Months Ended June 30, 2013 Ended June 30, 2012 Adjustments to: (a) Costs of goods sold: Employee stock-based compensation (1) (0.1) $ (0.0) $ Acquired inventory step -up value (2) (4.5) - Total (4.6) $ (0.0) $ (b) Research and
Slide 28: Historic Non-GAAP Operating Expense Leverage Ratios
Historic Non-GAAP Operating Expense Leverage Ratios 27 2010 2011 2012 Net Revenues - GAAP Basis 211.4 $ 264.3 $ 395.3 $ Pfizer Deferred Revenue Change in Estimate - - (92.0) Net Revenues - Non GAAP Basis 211.4 $ 264.3 $ 303.3 $ R&D - GAAP Basis 48.0 $ 61.9 $ 45.9 $ Stock Based Compensation (2.7) (3.
Auxilium Pharmaceuticals — Q2 2013 Earnings Presentation on 6ix